It was a busy week for Australia's top brokers. This has led to a number of broker notes being released.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:
Image source: Getty Images
Hub24 Ltd (ASX: HUB)
According to a note out of Bell Potter, its analysts have retained their buy rating and $110.00 price target on this investment platform provider's shares. The broker highlights that despite early weakness, global equity markets recovered and posted outsized returns for the June quarter. In light of this, Bell Potter has upgraded its model to reflect strong positive mark-to-markets. Outside this, the broker believes that a heavy decline since its November peak, despite earnings upgrades and further positive adjustments yet to flow through, has created a buying opportunity for investors. The Hub24 share price ended the week at $81.04.
Northern Star Resources Ltd (ASX: NST)
A note out of Citi reveals that its analysts have retained their buy rating and $29.70 price target on this gold miner's shares. The broker was pleased with Northern Star's quarterly update, which revealed gold sales comfortably ahead of expectations during the fourth quarter. It notes that this helped take Northern Star's gold sales beyond its revised guidance for FY 2026. As a result of this strong performance, Citi continues to see plenty of value in the company's shares at current levels. The Northern Star share price was fetching $22.16 at Friday's close.
ResMed Inc. (ASX: RMD)
Analysts at Morgans have retained their buy rating and $41.72 price target on this sleep disorder treatment company's shares. According to the note, the broker highlights that ResMed's shares have de-rated to just 16 times forward earnings. This is its lowest valuation in over a decade and comes despite the market continuing to forecast double-digit earnings per share growth. And while there are risks from GLP-1 therapies, an oral OSA therapy, and the potential re-entry of a key competitor next year, Morgans points out that current industry data and its operating performance provide limited evidence of a material deterioration in underlying demand. The ResMed share price ended the week at $30.50.
